Cordis, Abbott Continue Battle Over Stent Patents
Johnson & Johnson subsidiary Cordis Corp. has struck the most recent blow in its battle with Abbott Laboratories over the $2 billion annual U.S. market for drug-eluting coronary stents, filing a...To view the full article, register now.
Already a subscriber? Click here to view full article